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Short running title: A modified method for measuring antibiotic use

Synopsis
Objectives: To determine if adjusting the denominator of the common hospital antibiotic use measurement unit (DDD/100 bed-days), by including age-adjusted comorbidity score (100 bed-days/age-adjusted comorbidity score), would result in more accurate and meaningful assessment of hospital antibiotic use.
Methods: The association between the monthly sum of age-adjusted comorbidity and monthly antibiotic use was measured using time-series analysis (January 2008 to June 2012). For the purposes of conducting internal benchmarking, two antibiotic usage data sets were determined, i.e. 2004-2007 (first study period) and 2008-2011 (second study period). Monthly antibiotic use was normalized per 100 bed-days and per 100 bed-days/age-adjusted comorbidity score. 
Results: Results showed that antibiotic use had significant positive relationships with the sum of age-adjusted comorbidity score (p=0.0004). The results also showed that there was a negative relationship between antibiotic use and (i) alcohol-based hand rub use (p=0.0370) and (ii) clinical pharmacist activity (p=0.0031).  Normalizing antibiotic use per 100 bed-days contributed to a comparative usage rate of 1.31, i.e. the average antibiotic use during the second period was 31% higher than the first period. However, normalizing antibiotic use per 100 bed-days per age-adjusted comorbidity score resulted in a comparative usage rate of 0.98, i.e. the average antibiotic use was 2% lower in the second study period. Importantly, the latter comparative usage rate is independent of differences in patient density and case mix characteristics between the two studied populations. 
Conclusions: The proposed modified antibiotic measure provides an innovative approach to compare variations in antibiotic prescribing while taking account of patient case mix effects. 



























The evidence of a relationship between antibiotic use, and misuse on the development of antibiotic resistant bacteria, both at the individual and population level, has been documented. 1-4 This has subsequently increased morbidity, mortality and incurred additional hospital costs. 5, 6 Antibiotic resistance is a multifactorial problem that requires a multifactorial solution, of which optimising antibiotic use has been considered a key component. 7-9 The latter has been formalised through the establishment of hospital antibiotic stewardship programmes in a range of healthcare settings, which consist of a set of coordinated strategies to improve the use of antibiotic medications with the goal of enhancing patient health outcomes. 7-10 The surveillance of hospital antibiotic use and resistance patterns is considered a key aspect of high quality antibiotic stewardship implementation, evaluation and performance. To measure antibiotic use, the defined daily doses (DDD) per 100 bed-days method has been recommended by the World Health Organisation (WHO) Collaborating Centre for Drug Statistics and Methodology. 10,11 In healthcare settings, expressing antibiotic use as DDD per 100 patient days has been used as an indicator for antibiotic selection density (the proportion of patients receiving antibiotics in the hospital) and the selection pressure. However, this measure does not provide information on the number of patients actually exposed to antibiotics, possibly indicating the need for additional measurement units that will allow meaningful understanding of hospital antibiotic use. 12

Whereas there is a consensus regarding the role of antibiotic stewardship as a modality to improve patient care and healthcare outcomes, 7-10 the most appropriate method for quantifying and reporting hospital antibiotic use is still debatable. 12-14 Recently, an investigation, with the objective of evaluating the effect of age-adjusted comorbidity and alcohol-based hand rub on monthly hospital antibiotic usage, was carried out in the Antrim Area Hospital (Northern Ireland). The results showed that monthly antibiotic use was significantly related to the mean age-adjusted comorbidity index, a non-modifiable factor, indicating the possible utility of this variable in explaining hospital antibiotic use. 15 


















Setting and study design




Monthly antibiotic usage data, for hospitalised adult patients, were obtained from the pharmacy computer systems retrospectively and were converted into defined daily doses (DDDs). Monthly data for alcohol-based hand rub (ABHR/litres), clinical pharmacist full time equivalents (FTE) and occupied patient bed days were determined retrospectively from the hospital information system. Monthly hospital adult admissions, with their corresponding               age-adjusted co-morbidity data, were obtained from the Hospital Episode Statistics (HES). Age-adjusted co-morbidity score were calculated by combining age with the Charlson comorbidity index. 16-18 The Charlson score is a weighted index that includes 19 diagnoses, and each diagnosis is weighted according to a one year relative risk of mortality. The weighted index reflects the severity of each comorbid disease. 16-18 With age-adjusted co-morbidity, an additional score is added for age (i.e. one point is added for each decade over the age of 40 years). Following this, the summation of the monthly patient age-adjusted Charlson comorbidity score was calculated for inclusion in the analysis. The collection of data included the Intensive Care Unit (one 8-bedded unit).  Paediatrics were excluded from the study.

Enhanced antibiotic stewardship
Following a clostridium difficile infection (CDI) outbreak, the Northern Health and Social Care Trust devised an antibiotic policy to minimize the use of high-risk antibiotics (second-generation cephalosporins, third-generation cephalosporins, fluoroquinolones, and clindamycin; January 2008), and classified other antibiotics as medium-risk (amoxicillin-clavulanic acid and macrolides) or low-risk antibiotics (all remaining antibiotics; September 2008). 19, 20 Clinical staff were encouraged to adhere to the hospital policy and their compliance with the hospital policy was observed and recorded using a standardised procedure form. 21 The use of antimicrobials not included in the policy was monitored through exemption forms which required authorisation by a consultant physicians. The exemption forms were assessed by the Antimicrobial Management Team (AMT) as appropriate or inappropriate with a written explanation. Results were directly shared with the prescribing physicians. 

Antibiotic measure calculations
Antibiotic use was normalised per 100 bed-days and per 100 age-adjusted comorbidity score separately. A modified antibiotic usage measuring unit was devised to take into account both patient bed-days and patient comorbidity score, i.e. DDDs/100 bed-days/age-adjusted comorbidity [(number of antibiotic DDDs in a specific month/ (patient days x sum of age-adjusted comorbidity score in that month)) x 100]. Antibiotic comparative usage rate was calculated by dividing the average monthly antibiotic use during the second study period by the average monthly antibiotic use during the first study period. The latter was carried out considering all antibiotics, i.e. total antibiotics for systemic use (J01). However, to address possible effects with regards to changes in antibiotics volumes due to the restriction policy (i.e. an increase in amoxicillin and amoxicillin/clavulanic acid agents which may lead to an apparent increase in antibiotic use regardless of increased patient activity), another analysis that excluded all antibiotics involved in the restriction policy (i.e., second-generation cephalosporins, third-generation cephalosporins, fluoroquinolones, clindamycin, penicillins with extended spectrum, and combinations of penicillins including beta-lactamase inhibitors) was considered. Antibiotic comparative usage rate was also calculated for the latter and presented separately.

Statistical analysis













Analysis of data showed that monthly antibiotic use had significant positive relationships with the sum of age-adjusted comorbidity score (concomitant effect; coefficient= 0.927; p=0.0004; Table 1). This means that a level change in the sum of age-adjusted comorbidity score by 1% would cause a level change in antibiotic use by 0.927% (direct relationship). The results also showed that there was a negative relationship between antibiotic use and (i) alcohol-based hand rub use (two months delay; coefficient= -0.085; p=0.0370; Table 1) and (ii) clinical pharmacist FTE (three months delay; coefficient= -0.487303; p=0.0031; Table 1).  This means that a level change in alcohol-based hand rub use and clinical pharmacist FTE by 1% would cause a level change in antibiotic use by 0.085% and 0.487% (inverse relationship), respectively.





b.	The modified measure and benchmarking
Age-adjusted comorbidity score were calculated for 167,576 admissions. Distributions of comorbidity and age-adjusted comorbidity score are shown in Table 2. Data showed strong association between the monthly sum of age-adjusted comorbidity score and the monthly number of admissions (Pearson’s correlation=0.92, p= <0.0001). Over the two study periods (2004-2007 and 2008-2011), the average observed monthly antibiotic use was 8062.7 and 11407.6 DDDs, respectively, with an increased trend in antibiotic use being observed (p<0.0001; Table 3 and 4). Similar increasing trends were observed, for both study periods, when antibiotic use was normalised per 100 bed-days (p<0.000; Table 4). Characteristics and trends in monthly antibiotic use are shown in Table 3 and Table 4. The average monthly sum of age-adjusted comorbidity score, for both study periods, were 4194.3 and 5061.5, respectively; an increased trend was observed (p<0.0001; Table 4). When antibiotic use was normalized per age adjusted comorbidity and per bed-days/age adjusted comorbidity, a significant increasing trend was observed for the period 2004-2007 (p<0.0001 and p<0.0027, respectively). However, antibiotic use during the period 2008-2011 for both DDD/age-adjusted comorbidity score and DDD/100 bed-days/age-adjusted comorbidity score remained stable (p<0.1311 and p<0.6857, respectively; Table 4). Plots for the monthly antibiotic use (DDDs) versus use of antibiotics normalised per different denominators (i.e. bed-days, age-adjusted comorbidity score and bed-days/age-adjusted comorbidity score) are presented in Figure 2. A graph for antibiotic use DDD/100 bed-days versus (a) antibiotic use DDD/age-adjusted comorbidity scores and (b) DDD/100 bed-days/age-adjusted comorbidity score is shown in Figure 3.

















The process of developing policies and identifying targets for quality improvement in healthcare systems depends largely on the adequate collecting and interpretation of a range of quality indicators. Different sources of data, with several advantages and limitations, are available for quantifying hospital antibiotic use, including pharmacy purchases, patient prescription profiles, and pharmacy deliveries to wards. The latter data have been widely used for surveillance since it is easily accessible and readily available. The use of DDDs as a unit of measurement provides a reflection of the quantitative volumes of antibiotic usage and helps to enable comparisons between different institutions and countries. However, concerns have been expressed over which denominator should be used in order to express hospital antibiotic usage. 12-14 More importantly, it has been shown that antibiotic use varies widely between different hospitals, 29, 30 with several studies suggesting excessive use, thus making it difficult to conduct proper benchmarking across hospitals. 3, 31, 32 High antibiotic use in a particular setting is often justified by clinicians, as relating to differences in patient morbidities. 33-35 The measurement of patient comorbidity may therefore play a major role in explaining variations in hospital antibiotic use and subsequently facilitating the conduct of more realistic benchmarking.  

The results of the present research showed that monthly antibiotic use was significantly related to the age-adjusted co-morbidity score. The importance of measuring co-morbidity lies in its ability to predict morbidity, mortality, cost, hospitalisation, and the burden of the disease. 16-18 As such, this factor can provide risk-adjustment criteria for patient case-mix purposes and can have a vital role in explaining trends and variation in hospitals’ antibiotic use. 15 Interestingly, changing age-adjusted comorbidity score had a much higher impact within the model when compared with the two other significant variables (Table 1). The latter observation, together with the fact that patients’ age adjusted comorbidity role as a proxy measure for the disease burden has been proven, 16-18 suggested a possible utility for this non-modifiable variable as an appropriate denominator for the calculation and presentation of hospital antibiotic use.  The findings of the study also showed that an increase in the use of alcohol-based hand rub was associated with a decrease in antibiotic use. Antibiotics administered to patients in hospital are used to treat community and healthcare acquired infections. In relation to hospital, the use of alcohol based hand rub was shown as an effective method to reduce the spread and acquisition of healthcare acquired infections; the latter is associated with significant increase in length of hospital stay and antibiotic treatment. 24, 36, 37  It is interesting to note that variations in hospital pathogens’ prevalence might be followed by similar variations in pathogens’ prevalence in the surrounding community. The findings of MacKenzie et al. showed that monthly MRSA prevalence in the community was strongly related to the monthly MRSA prevalence observed one month before in the hospital, suggesting that the reason for the increase in MRSA prevalence in the community was a hospital MRSA outbreak. 38 Thus, increasing alcohol based hand rub, which is a proxy measure for adequate practiced infection control, might be leading to a subsequent reduction in hospital antibiotic use. However, further prospective research is needed to assess the impact of enhancing different infection control practices (e.g. alcohol based hand rub, surveillance activity, education, etc.) on antibiotic use in healthcare settings. 

In addition, the clinical pharmacy staffing levels full time equivalents was used as a proxy measure for clinical pharmacy activity. The results showed that an increase in the clinical pharmacy services provided across the hospital was associated with a decrease in antibiotic use. This is in line with other local research that showed that medicine appropriateness is improved via improved medication management by the clinical pharmacy team.39

In Antrim Area Hospital, a major C. difficile infection (CDI) outbreak occurred in 2008. 19 The CDI outbreak was ended following the implementation of an action plan that involved improving communication, infection control practices, environmental hygiene and surveillance, and enhanced antibiotic stewardship. 19 The latter involved the implementation, led by the Antimicrobial Management Team (AMT), of prospective audit of antimicrobial use with direct interaction and feedback to the prescriber, formulary restriction and a preauthorization strategy. 19, 21 With such high awareness of the problem of antibiotic use and resistance in this hospital, the statistically significant increasing usage trend and the observed 31% increase in average antibiotic use (DDD/100 bed-days) during the implementation of the enhanced antibiotic stewardship (the second study period; Table 4 and 5) contradicted the natural expected outcomes. Nevertheless, adjusting antibiotic usage DDDs per  age adjusted comorbidity score resulted in only a 6% antibiotic use increase during the enhanced antibiotic stewardship period, highlighting the value of considering patient case mix when expressing hospital antibiotic use. Such findings were consistent with the non-significant antibiotic use trend which was observed during the second study period (DDD/ age adjusted comorbidity; Table 4). However, taking into account a more robust unit of measurement (i.e. DDDs/100 bed-days/age-adjusted comorbidity score) has shown a reduction in the average antibiotic use by 2% (during the second study period). This reduction in antibiotic use together with the significant reduction in high risk antibiotics (described elsewhere), 19, 20 demonstrates the success of this antibiotic stewardship in the study site hospital and confirms its value in the management of hospital antibiotic use. 

The study has several strengths. Firstly, the employed statistical regression technique has taken cognizance of the problem of dependency existing between consecutive observations and for identifying lag effects between predictors and the outcome series, thus, measuring accurately significant relationships. 40 Secondly, the study used robust risk-adjustment criteria for patients’ case-mix (i.e. the Charlson Index) that is considered as the gold standard to assess comorbid risk in clinical research and uses readily available hospital databases. 16-18 
Thirdly, analysis showed a strong association between monthly sum of age-adjusted comorbidity score and number of monthly admissions. This is of importance since age-adjusted comorbidity score can reflect monthly changes in hospital admissions. Therefore, expressing antibiotic use in terms of age-adjusted comorbidity score may possibly account for variations in admission rates, and as such providing a meaningful understanding and interpretation of hospital antibiotic use. 12 Fourthly, antibiotic use and the age-adjusted comorbidity score were calculated for all hospitalised adult patients, thus, information and selection bias were unlikely. Finally, the confounding effect of different healthcare systems and hospital policies was adjusted for since the study used an internal benchmarking approach in the same study site hospital. 

However, the study has the following limitations. Firstly, although it is possible to argue that the increase in antibiotic use during the second study period was an apparent increase due to the increase in amoxicillin and amoxicillin/clavulanic acid, the exclusion of these agents showed similar patterns of decreasing overall antibiotic use when considering the presented adjustment measures (Table 5). Thus, indicating that the increase in antibiotic use was a genuine increase and possibly related to other different reasons.  Secondly, it is possible that other potential drivers for increased antibiotic use could be related to hospital infection rates and duration of treatment. Research from the study site Trust showed that the introduced intervention in 2008 (i.e. restricting high risk antibiotics) had positive impact on reducing the incidence rates of specific hospital pathogens (i.e. CDI, ESBLs, MRSA). 19, 20, 41, 42 In addition, the quality of antibiotic prescribing and adherence to guidelines was continuously scrutinised and improved. 21, 43 For example, adherence to the Trust antibiotic policy was improved after 2008 21, 43 compared to prior periods. 44 Thirdly, it was not possible to determine accurate data for the entire study period with regards to other type of infections (e.g. surgical site infections, ventilator-associated pneumonia, etc.) to assess its relation with antibiotic use and age-adjusted comorbidity score; this requires further prospective future research in different hospitals. However, the presence of multiple comorbidities is an indicator of patients in sub-optimal health that may be unable to mount an effective immune response to bacterial challenge, and as such might facilitate patient colonisation/infection with pathogens; age–adjusted comorbidity score provides a convenient measure for the latter.
Fourthly, the Charlson index might be limited in its applicability to complex processes of care and functional outcomes since it does not incorporate physiological data to assess severity of comorbid conditions and it does not include functional impairment attributable to pre-existing comorbid conditions. 17 Finally, further research is needed to compare antibiotic use by different hospital departments, and to evaluate the proposed benchmarking approach using external groups and involving several hospitals across different countries with high and low volumes of antibiotic use.  


In conclusion, the proposed modified antibiotic use unit of measurement provided an innovative approach to the measurement of actual trends in antibiotic use and to compare variations in antibiotic prescribing between hospitals taking account of the effect of patient case mix. It facilitated the evaluation of antibiotic stewardship more accurately, and can enable more informative benchmarking between hospitals. It is interesting to note that other identified predictors are considered modifiable factors, thus leaving room for quality improvement in antibiotic use. Age-adjusted comorbidity score calculations (utilising the Charlson Index) are relatively easy to apply, based on availability of clinical diagnosis. 17 In addition to expressing antibiotic use per 100 bed-days, hospitals should be encouraged to express their antibiotic use per 100 bed-days/age-adjusted comorbidity score in order to allow the calculation of a comparative usage rate, while taking into account the effect of patient case mix. Following the determination of the percentage difference in antibiotic use, based on the identified antibiotic comparative usage rate, antibiotic policy makers should investigate the reasons behind a high or low antibiotic usage rate, thus, identifying targets for quality improvement in the former and presenting best antibiotic prescribing practice for adoption by others in the latter. 
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Table 1. Estimates of time-series analysis model for monthly antibiotic use (R2 = 0.58).

Term	Lag timea	Coefficient (SE)b	T-ratio	P-value
Sum of age-adjusted comorbidity score	0	0.927000 (0.244047)	3.798450	0.0004
Alcohol-based hand rub (Litres/100 bed-days)	2	-0.085489 (0.039737)	-2.151364	0.0370
Clinical Pharmacist (FTE/100 bed-days)	3	-0.487303 (0.155512)	-3.133538	0.0031
Moving average (MA)	5	-0.625627 (0.124044)	-5.043594	< 0.0001
FTE: Full Time Equivalent
  a Represents the delay necessary to observe the effect (in months).




















Table 2. Distribution of comorbidity and age-adjusted comorbidity score in Antrim Area Hospital, 2004-2011
Terms	Scores	2004-2007 (n=76,479)	2008-2011 (n=91,097)























Antimicrobial class (ATC group)                                            	Average monthly antibiotic use (range); 2004-2007		Average monthly antibiotic use (range); 2008-2011
	DDDs	DDD/100 bed-days  	DDD/age-adjusted comorbidity score	DDD/100 bed-days/age-adjusted comorbidity score	% of J01 use (based on DDD/100 bed-days)		DDDs	DDD/100 bed-days	DDD/age-adjusted comorbidity score	DDD/100 bed-days/age-adjusted comorbidity score	% of J01 use (based on DDD/100 bed-days)
Tetracyclines (J01A)	111.1	1.22	0.0268	0.0003	1.38		600.1	5.98	0.1019	0.0010	5.16
Amphenicols (J01B)	2.1	0.22	0.0005	0.0000	0.25		1.8	0.22	0.0003	0.000003	0.19
Penicillins with extended spectrum (J01CA)	280.36	3.09	0.0676	0.0007	3.50		1465.46	14.61	0.2479	0.0025	12.62
Beta-lactamase sensitive penicillins (J01CE)	193.33	2.11	0.0457	0.0005	2.39		205.77	2.09	0.0364	0.0004	1.80
Beta-lactamase resistant penicillins (J01CF)	371.09	4.07	0.0887	0.0010	4.61		567.3	5.71	0.0993	0.0010	4.93






Trimethoprim and derivatives (J01EA)	187.35	2.06	0.0450	0.0005	2.33		334.18	3.38	0.0583	0.0006	2.92











Antibiotics for systemic use, Total (J01)	8062.67	88.7	1.9179	0.0211	100.00		11407.55	115.8	2.0320	0.0207	100.00










Sum of age adjusted comorbidity scores	23.60427	<0.0001	44.18167	<0.0001
Total antibiotic DDD	104.7636	<0.0001	112.3938	<0.0001
Antibiotic use (DDD/100 bed-days)	0.924069	<0.0001	0.834901	<0.0001
Antibiotic use (DDD/age-adjusted comorbidity score)	1.391882	<0.0001	0.388966	0.1311

























Estimates including all antibiotics			
Antibiotic use (DDD/100 bed-days)	88.7	115.8	1.31
Antibiotic use (DDD/age adjusted comorbidity)	1.918	2.032	1.06
Antibiotic use (DDD/100 bed-days/age adjusted comorbidity)	0.0211	0.0207	0.98
			
Estimates excluding specific antibiotics **			
Antibiotic use (DDD/100 bed-days)	36.66	56.90	1.55
Antibiotic use (DDD/age adjusted comorbidity)	0.786	0.995	1.27




* This period represents the introduction of the enhanced antibiotic stewardship





























Figure 3. Monthly hospital antibiotic use, DDD/100 bed-days versus (A) antibiotic use, DDD/100 age-adjusted comorbidity score and (B) antibiotic use, DDD/100 bed-days/age-adjusted comorbidity score, January 2004 to December 2011, Antrim Area Hospital. January 2008 represents the introduction of the enhanced antibiotic stewardship. 
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